Adverum Biotechnologies, Inc. (ADVM) Stock

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a single injection into the vitreous humor of the eye. This treatment is being developed for individuals afflicted with persistent retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies maintains licensing and collaborative partnerships with institutions such as the University of California and Cornell University, as well as companies like GenSight, Lexeo, and Virovek. Established in 2006, the organization was initially named Avalanche Biotechnologies, Inc. before rebranding to Adverum Biotechnologies, Inc. in May 2016. Its headquarters are situated in Redwood City, California.

Adverum Biotechnologies, Inc. is headquartered in US.

Adverum Biotechnologies, Inc. (ADVM) stock trades at $4.36 with a market capitalization of $96.26M. The stock is valued at a price-to-earnings (P/E) ratio of -0.66, price-to-book of -1.84, price-to-sales of 96.26. Over the past 52 weeks the stock has ranged between $1.78 and $6.07, and currently trades 28.2% below its 52-week high.

On profitability, Adverum Biotechnologies, Inc. generates a return on equity (ROE) of 872.77% — well above the market average, a sign of a high-quality business, return on capital employed of -524.73%, an operating margin of -13900.00%, a net profit margin of -13100.00%.

Official website: www.adverum.com